En Es
Categories

Industry News

Medix Biochemica Acquires IVD Raw Materials Producer Bioresource Technology

By Labmedica International staff writers
21 Jun 2022

Image: Medix Biochemica has broadened its capabilities in diagnostic base matrices through the acquisition of BRT (Photo courtesy of Pexels)

Medix Biochemica (Espoo, Finland) has acquired 100% of the shares of Bioresource Technology (BRT, Weston, FL, USA) to broaden its base matrix capabilities and further strengthen its local presence in the US market. As a result of this partnership, Medix will provide its customers with a comprehensive offering of raw materials for their in vitro diagnostics (IVD) quality control products.


BRT is a leading provider of high-quality base matrices and other critical raw materials to many of the largest IVD manufacturers across the world, with a focus on manufacturing immunoassay, clinical chemistry and molecular diagnostic assay and QC materials. BRT’s organization and operations will form a significant part of Medix’s IVD Biomaterials Business Unit, which also comprises manufacturing of native antigens, enzymes, proteins and biological.


“Together, we have the potential to broaden our offering to IVD companies across the globe,” said Steve Ferguson, CEO of Medix Biochemica. “There is an excellent complementary offering between our portfolios, enabling Medix Biochemica to be a comprehensive partner for IVD companies requiring quality raw materials for QC products. With our complete offering of biological samples, processed plasma, base matrices, native enzymes, proteins, antibodies or antigens and our depth of expertise, we can dramatically reduce time to market for IVD companies whatever their need. Our vision is to be the first-choice partner for the IVD industry, and the team at BRT takes us one step closer.”


“We are excited about joining Medix Biochemica,” addd Derik Reichenbach, President of BRT. “Building long-term relationships with our customers have always been key to our success and together with Medix Biochemica’s global team, we are now able to reach even more IVD customers across the globe. We are very much looking forward to contributing to the strong growth of Medix Biochemica.”


Related Links:
Medix Biochemica 
Bioresource Technology 



E-mail Print
FaceBook Twitter Google+ Linked in

MEDIX BIOCHEMICA AB

Develops, produces and markets monoclonal antibodies, antibody services and recombinant antigens for IVD industry, as well as POC tests for human healthcare
Silver member
More info

More articles about MEDIX BIOCHEMICA AB

04 Mar 2022
Medix Biochemica Launches Refreshed and Expanding Brand to Reflect Growing IVD Products Portfolio
Medix Biochemica (Finland) is launching a rejuvenated brand to reflect both the improvements to its offering as a result of recent acquisitions, and its ongoing commitment to the in vitro diagnostics (IVD) industry.
Read More

Additional news

27 Jun 2022
Robot-Assisted Surgical Devices Market Driven by Increased Demand for Patient-Specific Surgeries
Given the growing incidence of lifestyle diseases and demand for affordable healthcare, effective surgery using robotic devices can result in a decline in treatment costs and drive the growth of the global robot-assisted surgical devices (RASD) market.
Read More
24 Jun 2022
Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests
Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction of customary closing conditions.
Read More
23 Jun 2022
Hospital Microbiology Testing Market Driven by Increasing Prevalence of Chronic Diseases
Rising medical expenditure as well as the presence of well-established modern healthcare infrastructure in various developed as well as developing regions is fueling the growth of the global hospital microbiology testing market.
Read More
22 Jun 2022
Global Minimally Invasive Surgery (MIS) Market to Surpass USD 325 Billion by 2031
The global MIS market is projected to surpass USD 325 billion by 2031, driven by growing patient awareness of the advantages of MIS over open surgeries, continuous innovation in surgical robots, and constant advancements in other MIS-associated technologies during the 2022-2031 forecast period.
Read More
21 Jun 2022
Global Bedside Testing Market to Witness Promising Prospects in Critical Care
Point-of-care or point-of-use diagnostics, also known as bedside testing, has gained increased prominence in analytical testing over the past few years as it provides clinically relevant information without the need for a dedicated laboratory.
Read More
20 Jun 2022
Global Sepsis Diagnostics Market Driven by Rising Hospital-Acquired Illnesses
The global sepsis diagnostics market is expected to grow at a CAGR of 8.3% during the period 2022-2028 to reach almost USD 0.88 billion by 2028, driven by a rise in the number of hospital-acquired illnesses and the rapidly growing molecular diagnostics market, although the high cost of automated diagnostic instruments could hamper market growth.
Read More
14 Jun 2022
BD Partners with Mayo Clinic Platform for Access to World's Largest Collection of Clinical Data
Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) has entered into a collaboration with Mayo Clinic Platform (Rochester, MN, USA) to access de-identified patient data from Mayo Clinic Platform_Discover.
Read More
14 Jun 2022
Quidel Partners with Global Lyme Alliance, Leads in Lyme Disease Testing
Quidel Corporation (San Diego, CA, USA) is joining forces with Global Lyme Alliance (Stamford, CT, USA) to heighten public awareness around Lyme disease during Lyme Disease Awareness Month (in May) and beyond.
Read More
09 Jun 2022
BD and Certest Collaborate on Monkeypox Molecular Diagnostic Test
Becton, Dickinson and Company (BD Franklin Lakes, NJ, USA) and CerTest Biotec (Zaragoza, Spain) have entered into a collaboration to develop a molecular diagnostic test for the Monkeypox virus.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions